Marc Evanchik, MS

Marc Evanchik is Senior Vice President of Pharmacology and Translational Medicine at Braveheart Bio, where he leads research and development efforts that connect early scientific discovery with clinical advancement. 

Marc brings deep expertise in pharmacology and over 20 years of experience developing innovative therapies. Earlier in his career, he helped pioneer the first-in-class therapy mavacamten, a breakthrough treatment targeting the underlying mechanics of hypertrophic cardiomyopathy (HCM). His research demonstrated that modulating cardiac muscle contraction could reduce thickening and stiffness of the heart, laying the foundation for a new approach to treating HCM. 

He is also an inventor on multiple patents related to novel treatments for heart muscle disorders and cardiac remodeling. 

At Braveheart Bio, Marc leads programs focused on advancing precision medicines for cardiac hypertrophy, diastolic dysfunction, and other heart-muscle diseases. 

‍